Why Prioritizing Patients Changes How Study Teams Approach DHTs

While technology offers extensive opportunities to enhance clinical trial efficiency and gain valuable patient insights, many sponsors and CROs face challenges in adopting and deploying these innovations. The team at ActiGraph has dedicated years to collaborating closely with study teams, integrating wearable digital health technologies (DHTs) into their research, and becoming well-versed in the operational intricacies that can influence the success or failure of remote DHT assessments.

To achieve the ultimate goal of patient-centered drug development, the study design, including DHT implementation, should revolve around the participants' needs. Sponsors must thoughtfully consider how and why DHTs are utilized in a study and effectively communicate this information to the participants. No matter how advanced a wearable device may be, it becomes worthless if the participant doesn't wear it.

Based on Actigraph's experiences, the authors have compiled three vital considerations to maximize participant adherence and ensure operational success. Access the full article to read the top considerations when using DHTs to support patient-centered drug development.